BRCA1 BRCT domains (human, recombinant)

The BRCA1 C-terminal (BRCT) domain is a modular unit of ~100 amino acids that folds independently and recognizes linear phosphoserine or phosphothreonine regions to mediate protein-protein and protein-DNA interactions. BRCT domains were initially recognized in the C-terminal region of the breast cancer protein BRCA1, as well as the p53 binding protein (53BP1, TP53BP1), and the yeast cell cycle checkpoint protein RAD9. BRCT domains often occur as tandem repeats at the C-terminal end of several proteins that are functionally diverse. Most BRCT domain-containing proteins participate in DNA-damage checkpoint control or DNA-repair pathways, or both. Thus, BRCT domain-containing proteins likely participate in the cellular response to DNA damage. Germ-line mutations of the tumor suppressor genes BRCA1 and BRCA2 pre-dispose women to familial breast and ovarian cancer and are associated with approximately 10% of the cases. The carboxy-terminal BRCT domain in BRCA1 is involved in DNA repair and transcriptional activation. The BRCT region of BRCA1 binds phosphorylated BACH1, a DEAH helicase, which is essential for mediating repair of DNA double-strand breaks by controlling G2 to M phase transition during cell cycle progression. BRCA1 also contains an N-terminal protein-protein-interaction RING-finger domain, that partners with BRCA1-associated RING domain 1 (BARD1). The BRCA1/BARD1 heterodimer maintains genomic stability by regulating DNA damage repair and ubiquitination. This product contains the BRCT domains of BRCA1.Synonyms: Breast Cancer Type 1 Susceptibility Protein. Purity: >90% (estimated by SDS-PAGE). Source: Recombinant N-terminal GST-tagged protein expressed in E. coli. MW: 53.3 kDa. Formulation: (Request formulation change), 50 mM Tris-HCl, pH 8.0, with 150 mM sodium chloride, and 20% glycerol. UniProt Accession #: P38398.